Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 5/20 | 0.51 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.45 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.45 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.45 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.42 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.42 |
| ▸ | NT5E | P21589 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21750463 | 1.00 | TYMP (0.51) | TYMPP2RX3P2RX4P2RX2PRMT6 | |
| SCHEMBL27135325 | 0.92 | TYMP (0.56) | TYMPADORA1ENPP1P2RY12ADORA2A | |
| SCHEMBL27028364 | 0.92 | TYMP (0.56) | TYMPADORA1ENPP1P2RY12ADORA2A | |
| SCHEMBL21284182 | 0.91 | TYMP (0.48) | TYMPPRMT6ADORA1P2RY12ADORA2A | |
| SCHEMBL20806099 | 0.91 | TYMP (0.48) | TYMPPRMT6ADORA1P2RY12ADORA2A | |
| SCHEMBL22034198 | 0.91 | TYMP (0.50) | TYMPPRMT6ADORA1P2RY12ADORA2A | |
| SCHEMBL29792969 | 0.91 | TYMP (0.49) | TYMPPRMT6ADORA1P2RY12ADORA2A | |
| SCHEMBL22034202 | 0.91 | TYMP (0.49) | TYMPPRMT6ADORA1P2RY12ADORA2A | |
| SCHEMBL18917304 | 0.91 | TYMP (0.49) | TYMPPRMT6ADORA1P2RY12ADORA2A | |
| SCHEMBL21245356 | 0.90 | TYMP (0.58) | TYMPADORA1P2RY12ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3621624-B1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME LLC (US) | 2023-08-30 | — | — | EP | disclosed |
| US-11466047-B2 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME LLC (US) | 2022-10-11 | — | — | US | disclosed |
| US-20200062798-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11466047-B2 | Cyclic di-nucleotide compounds as sting agonists | STING1, CGAS, IFNAR1 | TYMP 2012/4885P2RX3 111/4885P2RX4 147/4885 |
| US-20200062798-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | STING1, CGAS, IFNAR1 | TYMP 2012/4885P2RX3 111/4885P2RX4 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.